Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Summary

This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following interventions: * Atezolizumab * Bevacizumab * Stereotactic body radiation therapy (SBRT)

Timeline

Start

2022-08-23

Primary completion

2027-01-31

Completion

2032-01-31

Drugs

Indications